1. Anticalins in Drug Development

   • Steffen Schlehuber
   • Arne Skerra

   Drug Development 15 August 2012 Pages: 279 - 288

   

2. Toward Personalized Immunotherapy for Non-Hodgkin Lymphoma

   • Anne C. Armstrong
   • Eleanor J. Cheadle
   • Robert E. Hawkins

   Mechanisms and Targets 15 August 2012 Pages: 289 - 297

   

3. Mechanisms of Action for Treatments in Multiple Sclerosis

   • Michel Chofflon

   Mechanisms and Targets 15 August 2012 Pages: 299 - 308

   

4. The Role of Radioimmunotherapy with Yttrium- 90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma

   • Bruce D. Cheson

   Therapy Review 15 August 2012 Pages: 309 - 322

   

5. Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis

   • David Murdoch
   • Katherine A. Lyseng-Williamson

   Adis Spotlight 15 August 2012 Pages: 323 - 325

6. Darbepoetin Alfa

   • Dean M. Robinson
   • Stephanie E. Easthope

   Adis Drug Evaluation 15 August 2012 Pages: 327 - 343